A phase IIa study of cannabidiol for the treatment of Acute Graft versus Host Disease
Phase of Trial: Phase II
Latest Information Update: 24 Feb 2017
At a glance
- Drugs Cannabidiol (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors TALENT Biotech
- 24 Feb 2017 New trial record
- 22 Feb 2017 Results published in Kalytera Therapeutics a media release.
- 16 Feb 2017 According to a Kalytera Therapeutics media release, results from the study will be discussed in a conference call and webcast to be held on Thursday, February 23, 2017 at 12:00 PM ET.